TW200612918A - Lonidamine analogs - Google Patents

Lonidamine analogs

Info

Publication number
TW200612918A
TW200612918A TW094126067A TW94126067A TW200612918A TW 200612918 A TW200612918 A TW 200612918A TW 094126067 A TW094126067 A TW 094126067A TW 94126067 A TW94126067 A TW 94126067A TW 200612918 A TW200612918 A TW 200612918A
Authority
TW
Taiwan
Prior art keywords
lonidamine analogs
lonidamine
analogs
bph
cancer
Prior art date
Application number
TW094126067A
Inventor
Mark Matteucci
Photon Rao
Jian-Xin Duan
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US59283304P priority Critical
Priority to US59272304P priority
Priority to US59966604P priority
Priority to US64618805P priority
Priority to US65170505P priority
Priority to US66106705P priority
Priority to US68308705P priority
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of TW200612918A publication Critical patent/TW200612918A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring-systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

Lonidamine analogs are useful in the treatment of cancer and BPH.
TW094126067A 2004-07-29 2005-07-29 Lonidamine analogs TW200612918A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US59283304P true 2004-07-29 2004-07-29
US59272304P true 2004-07-29 2004-07-29
US59966604P true 2004-08-05 2004-08-05
US64618805P true 2005-01-21 2005-01-21
US65170505P true 2005-02-09 2005-02-09
US66106705P true 2005-03-11 2005-03-11
US68308705P true 2005-05-19 2005-05-19

Publications (1)

Publication Number Publication Date
TW200612918A true TW200612918A (en) 2006-05-01

Family

ID=35787877

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126067A TW200612918A (en) 2004-07-29 2005-07-29 Lonidamine analogs

Country Status (2)

Country Link
TW (1) TW200612918A (en)
WO (1) WO2006015263A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1869000A1 (en) 2005-03-31 2007-12-26 Pfizer Products Incorporated Cyclopentapyridine and tetrahydroquinoline derivatives
CN101501054B (en) 2005-06-29 2012-09-05 施瑞修德制药公司 Phosphoramidate alkylator prodrugs
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
EP2610244A1 (en) 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
PT2065388E (en) 2006-09-19 2011-11-10 Daiichi Sankyo Co Ltd Pyrazolopyrimidine derivative
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinone derivatives
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinone derivatives
EA201001094A1 (en) * 2008-02-29 2011-04-29 Пфайзер Инк. Derivatives indazols
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinone derivatives
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008037790A1 (en) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
AU2009331990B2 (en) 2008-12-22 2016-04-14 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
TWI441829B (en) 2009-02-25 2014-06-21 Daiichi Sankyo Co Ltd Tricyclic pyrazolopyrimidine derivatives
CA2809388A1 (en) 2010-08-23 2012-03-01 Daiichi Sankyo Company, Limited Crystal of a free tricyclic pyrazolopyrimidine derivative
EP2810945A1 (en) 2010-08-23 2014-12-10 Daiichi Sankyo Company, Limited Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative
AR084433A1 (en) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc FAAH inhibitors and pharmaceutical compositions containing them
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI664164B (en) 2014-02-13 2019-07-01 美商英塞特控股公司 Cyclopropylamines as lsd1 inhibitors
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
JP2017506248A (en) * 2014-02-20 2017-03-02 コーネル ユニヴァーシティー Compounds and methods for inhibiting fascin
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2016306555A1 (en) 2015-08-12 2018-03-15 Incyte Corporation Salts of an LSD1 inhibitor
US20190016680A1 (en) * 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2017121693A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituted thiazole and thiadiazole amides, and use thereof
KR20190018628A (en) 2016-04-22 2019-02-25 인사이트 코포레이션 Formulation of LSD1 inhibitor
EP3564214A1 (en) 2018-05-04 2019-11-06 Universita' Degli Studi G. D Annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system

Also Published As

Publication number Publication date
WO2006015263A2 (en) 2006-02-09
WO2006015263A3 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
DK1583542T3 (en) Compositions and Methods for Antiviral Combination Therapy
CA113565S (en) Bottle
DK1572106T3 (en) Method for the prevention and treatment of cancer metastasis and bone loss associated with cancer metastasis
CA115720S (en) Lid
AU2004241093B2 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
CA113465S (en) Showerhead
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
FR2869231A1 (en) Therapeutic composition containing at least one pyrrolobenzodiazepine derivative and fludarabine
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
SG10201811480WA (en) Therapeutic compounds and compositions
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
EP1565187A4 (en) Methods of treating cancer and related methods
MXPA04002593A (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
MXPA06014510A (en) Compositions and methods for treating inflammatory disorders.
EP1587519A4 (en) Treatment of cancer with 2-deoxyglucose
EP1613308A4 (en) Novel methods for the treatment of cancer
NZ579644A (en) Antibodies against erbb3 and uses thereof
ZA200507752B (en) Compositions and methods for treating cancer
EP1589933A4 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
AT553198T (en) Treatment of cancer by the combined inhibition of proteasome and telomerase activities
SG164368A1 (en) Treatment of cancer